論文 - 永田 賢治
-
[Antiphospholipid syndrome with autoimmune hemolytic anemia which mimics thrombotic thrombocytopenic purpura].
Karasawa N, Taniguchi Y, Hidaka T, Katayose K, Kameda T, Side K, Shimoda H, Nagata K, Kubuki Y, Matsunaga T, Shimoda K
[Rinsho ketsueki] The Japanese journal of clinical hematology 51 ( 4 ) 275 - 80 2010年4月
記述言語：日本語 掲載種別：研究論文（学術雑誌）
-
血栓性血小板減少性紫斑病との鑑別を要した自己免疫性溶血性貧血合併抗リン脂質抗体症候群
唐澤 直希, 谷口 康博, 日高 智徳, 片寄 恵子, 亀田 拓郎, 幣 光太郎, 下田 晴子, 永田 賢治, 久冨木 庸子, 松永 卓也, 下田 和哉
臨床血液 51 ( 4 ) 275 - 280 2010年
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：一般社団法人 日本血液学会
倦怠感を主訴に受診した67歳女性が，発熱，溶血性貧血，血小板減少，変動する意識障害等を呈した。直接クームス試験陽性，抗cardiolipin<i>β</i>2-glycoprotein I抗体，ループスアンチコアグラント陽性であり，autoimmune hemolytic anemia (AIHA)を合併したantiphospholipid syndromeと診断した。変動性意識障害，左右失認，失算，失書を認め，頭部MRIで多発性脳梗塞の所見を呈しており，優位大脳半球梗塞を合併していた。換気血流シンチで換気血流ミスマッチを認め肺梗塞を併発していた。下肢CTで両側下腿静脈，両側膝窩静脈，右大腿静脈に血栓を認め深部静脈血栓症を併発していた。臨床症状よりthrombotic thrombocytopenic purpuraとの鑑別を要したが，ADAMTS-13活性正常であることより否定的であった。AIHAに対しプレドニゾロン45 mg (1 mg/kg)，血栓症に対しワーファリン3 mg, 低分子ヘパリン3,500単位による抗凝固療法を開始し症状の改善を認めた。
-
Uto H., Stuver S., Hayashi K., Kumagai K., Sasaki F., Kanmura S., Numata M., Moriuchi A., Hasegawa S., Oketani M., Ido A., Kusumoto K., Hasuike S., Nagata K., Kohara M., Tsubouchi H.
Hepatology 50 ( 2 ) 393 - 399 2009年11月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Hepatology
The overall mortality of patients infected with hepatitis C virus (HCV) has not been fully elucidated. This study analyzed mortality in subjects positive for antibody to HCV (anti-HCV) in a community-based, prospective cohort study conducted in an HCV hyperendemic area of Japan. During a 10-year period beginning in 1995, 1125 anti-HCV-seropositive residents of Town C were enrolled into the study and were followed for mortality through 2005. Cause of death was assessed by death certificates. Subjects with detectable HCV core antigen (HCVcAg) or HCV RNA were considered as having hepatitis C viremia and were classified as HCV carriers; subjects who were negative for both HCVcAg and HCV RNA (i.e., viremia-negative) were considered as having had a prior HCV infection and were classified as HCV noncarriers. Among the anti-HCV-positive subjects included in the analysis, 758 (67.4%) were HCV carriers, and 367 were noncarriers. A total of 231 deaths occurred in these subjects over a mean follow-up of 8.2 years: 176 deaths in the HCV carrier group and 55 in the noncarrier group. The overall mortality rate was higher in HCV carriers than in noncarriers, adjusted for age and sex (hazard ratio, 1.53; 95% confidence interval, 1.13-2.07). Although liver-related deaths occurred more frequently among the HCV carriers (hazard ratio, 5.94; 95% confidence interval, 2.58-13.7), the rates of other causes of death did not differ between HCV carriers and noncarriers. Among HCV carriers, a higher level of HCVcAg (≥100 pg/mL) and persistently elevated alanine aminotransferase levels were important predictors of liver-related mortality. Conclusion: The presence of viremia increases the rate of mortality, primarily due to liver-related death, among anti-HCV-seropositive persons in Japan. Copyright © 2009 by the American Association for the Study of Liver Diseases.
DOI： 10.1002/hep.23002
-
Hidaka T., Shide K., Shimoda H., Kameda T., Toyama K., Katayose K., Kubuki Y., Nagata K., Takenaka K., Akashi K., Okamura T., Niho Y., Mizoguchi H., Omine M., Ozawa K., Harada M., Shimoda K.
European Journal of Haematology 83 ( 4 ) 328 - 333 2009年10月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：European Journal of Haematology
Cytogenetic abnormalities were often observed in primary myelofibrosis patients. The presence of specific cytogenetic abnormalities, such as sole abnormalities of chromosome 13q-, 20q-, or -7/7q-, is reported to have the influence on the prognosis of primary myelofibrosis. We analyzed the data from the prospective survey of Japanese primary myelofibrosis patients which was conducted from 1999 to clarify the impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis. A total of 202 primary myelofibrosis patients had the cytogenetic and the prognostic data. Eighty (40%) out of 202 cases had cytogenetic abnormalities, and an association was evident for platelet counts. Although the presence of an abnormal karyotype did not affect the prognosis, primary myelofibrosis patients with cytogenetic abnormalities other than 13q- and 20q- showed an inferior prognosis compared to patients with a normal karyotype or sole 13q- or 20q- abnormalities. Patients with an unfavorable cytogenetic profile (abnormal cytogenetics other than 13q- or 20q-) also had a greater tendency to transform to leukemia than patients with a favorable cytogenetic profile (normal cytogenetics, sole abnormalities of either chromosome 13q-, or 20q-). Abnormal cytogenetics other than 13q- or 20q- in primary myelofibrosis patients has the poor prognostic effect for both survival and the risk of leukemic transformation. © 2009 John Wiley & Sons A/S.
-
食道静脈瘤上に発生し, 内視鏡的に治療しえた食道上皮内癌の1例
原田 拓, 山本 章二朗, 田原 良博, 三池 忠, 安倍 弘生, 山路 卓巳, 中村 憲一, 楠元 寿典, 岩切 久芳, 蓮池 悟, 永田 賢治, 下田 和哉
日本消化器内視鏡学会雑誌 = Gastroenterological endoscopy 51 ( 8 ) 1692 - 1699 2009年8月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Japan Gastroenterological Endoscopy Society
69歳女性．B型+アルコール性肝硬変による食道静脈瘤上に不整発赤を認め，NBI（narrow band imaging）併用拡大内視鏡にて上皮内癌と診断した．静脈瘤の治療後（内視鏡的硬化療法，食道静脈瘤結紮術，クリッピング）に超音波内視鏡にて血管消失を確認し，癌病変の内視鏡的粘膜切除術を安全に施行できた．同様の症例では上述の非侵襲的検査を適切に組み合わせて用いることが非常に有用であると思われた．
DOI： 10.11280/gee.51.1692
-
Harada T., Yamamoto S., Tahara Y., Miike T., Abe H., Yamaji T., Nakamura K., Kusumoto K., Iwakiri H., Hasuike S., Nagata K., Shimoda K.
Gastroenterological Endoscopy 51 ( 8 ) 1692 - 1699 2009年8月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Gastroenterological Endoscopy
We here report a case with esophageal cancer located on solely esophageal varices, requiring an endoscopic mucosal resection. A 69-year-old woman was referred to our hospital for further evaluation of the with an esophageal lesion suspected of being a superficial cancer. On upper gastrointestinal endoscopy, a slightly depressed, superficial, reddish lesion located solely on esophageal varices was found, it was diagnosed as a superficial esophageal cancer using special endoscopic techniques. Treatment was first performed for the esophageal varices using endoscopic procedures (endoscopic injection sclerotherapy (EIS), endoscopic variceal ligation (EVL), and endoscopic clipping). After eradication of the varices, the disappearance of vessels under the cancer was confirmed by endoscopic ultrasonography (EUS). Since then, endoscopic mucosal resection (EMR) of the cancer lesion was carried out without the occurence of any severe complications. On histopathology, the intraepithelial cancer, was found to have been completely resected without lymphatic or vascular permeation. The approach used in this patient is useful for the diagnosis and the treatment of superficial esophageal cancer located solely on varices.
-
永田 賢治, 下田 和哉
臨床病理 57 ( 4 ) 357 - 364 2009年4月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：日本臨床検査医学会事務所
-
Myeloproliferative diseases caused by JAK2 mutation
Nagata K., Shimoda K.
Rinsho byori. The Japanese journal of clinical pathology 57 ( 4 ) 357 - 364 2009年4月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Rinsho byori. The Japanese journal of clinical pathology
Polycythemia vera (PV), essential thrombocythemia(ET), and primary myelofibrosis (PMF) share common clinical features, being clonal disorders of multipotent progenitors. In 2005, a somatic activating mutation in JAK2 (V617F) was identified in most patients with PV and in about half of patients with ET or PMF. The JAK2 mutation causes the constitutive activation of the JAK-STAT signaling pathway, and leads to autonomous cell growth in a cytokine-independent manner. A higher expression of JAK2 V617F would favor erythrocytosis, and a lower one would favor thrombocytosis. This may suggest that the expression levels of JAK2 V617F directly determine which cell lineages increase, possibly leading to the diversity of myeloproliferative diseases. Although only V617F JAK2 may cause myeloproliferative disease (MPD), clonogenic assay, analysis of familial MPD patients, and examination of JAK2 mutation in acute leukemia patients transformed from MPD show that there are additional somatic mutations which contribute to the pathogenesis of V617F JAK2 positive PV, ET, and PMF.
-
胃前庭部の嵌頓柿胃石に対してコーラによる溶解療法が奏功した1例
原田 拓, 井上 龍二, 有馬 志穂, 黒木 和男, 田原 良博, 三池 忠, 安倍 弘生, 山本 章二朗, 楠元 寿典, 蓮池 悟, 永田 賢治, 下田 和哉
日本消化器内視鏡学会雑誌 = Gastroenterological endoscopy 50 ( 12 ) 3033 - 3039 2008年12月
記述言語：日本語 掲載種別：研究論文（学術雑誌）
-
Takahama Y., Uto H., Kanmura S., Oketani M., Ido A., Kusumoto K., Hasuike S., Nagata K., Hayashi K., Stuver S., Okayama A., Tsubouchi H.
Journal of Gastroenterology 43 ( 12 ) 942 - 950 2008年12月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Journal of Gastroenterology
Background: The clinical course of chronic hepatitis C virus (HCV) infection is strongly associated with insulin resistance and obesity. The K121Q polymorphism in the ectonucleotide pyrophosphatase/ phosphodiesterase (ENPP)-1 gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with insulin resistance and obesity. This study examined whether the K121Q polymorphism in ENPP1 or the rs7566605 genotype is associated with the clinical course of HCV infection. Methods: The relationships between the clinical characteristics of 469 anti-HCV antibody-seropositive subjects (353 were positive for HCV core antigen or RNA, whereas 116 were negative for HCV RNA) and the polymorphisms were analyzed. Results: No significant differences in body mass index, plasma glucose level, serum insulin level, and other biochemical markers were observed between subgroups of subjects with different genotypes at the K121Q polymorphism or rs7566605. The frequency of the homozygous wild-type genotype at K121Q in HCV carriers, however, was significantly higher than that in subjects who were negative for HCV RNA (84.5% vs. 75.9%; P < 0.05). Moreover, in HCV carriers, HCV core antigen levels in subjects homozygous for the wild-type genotype at K121Q were significantly higher than in heterozygous carriers of K121Q (5358 fmol/l vs. 4002 fmol/l; P = 0.04). In contrast, the rs7566605 genotype was not associated with hepatitis C viremia or with the HCV core antigen level. Conclusions: The K121Q variant of ENPP1 may be associated with hepatitis C viremia and core antigen levels in HCV carriers. © Springer Japan 2008.
-
Miike T., Tahara Y., Yamaguchi Y., Harada T., Abe H., Kusumoto K., Numata M., Hasuike S., Yamamoto S., Kodama M., Nagata K., Hayashi K., Shimoda K.
Japanese Journal of Gastroenterology 105 ( 9 ) 1362 - 1366 2008年12月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Japanese Journal of Gastroenterology
A 66-year-old man patient with chronic hepatitis (CH) C and complications from ulcerative colitis (UC) was treated with interferon-beta (IFN-β). Endoscopically, the UC disease activity was moderate before IFN-β treatment but was in remission eight week after treatment. However, a few months after stopping IFN treatment, endoscopy revealed that the UC disease activity had returned to moderate levels. This result shows that UC improved with IFN treatment.
-
Harada T., Inoue R., Arima S., Kuroki K., Tahara Y., Miike T., Hiroo A., Yamamoto S., Kusumoto K., Hasuike S., Nagata K., Shimoda K.
Gastroenterological Endoscopy 50 ( 12 ) 3033 - 3039 2008年12月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Gastroenterological Endoscopy
We report a case of impacted diospyrobezoars in gastric antrum, which were treated successfully by dissolution therapy with Coca-Cola administration. An 87-year-old woman was admitted to our hospital because of abdominal pain and feeling of abdominal distension. Upper gastrointestinal endoscopy revealed two diospyrobezoars (each size was 7cm and 3cm in diameter) in the stomach, and one bezoar became impacted in gastric antrum at a later date. The endoscopic removal using forceps and polypectomy snare resulted in failure. Therefore, she received dissolution therapy with Coca-Cola. On the next day, the impacted bezoar was partially dissolved and turned to be softened, and that was safely-removed endoscopically. She took extra dose of Coca-Cola, and the next day, remaining bezoars were completely dissolved. The dissolution therapy with Coca-Cola may be useful in patients with diospyrobezoars resistant to endoscopic therapy.
-
C型慢性肝炎に対するインターフェロンβ投与にて潰瘍性大腸炎が改善した1例
三池 忠, 田原 良博, 山口 由美, 原田 拓, 安倍 弘生, 楠元 寿典, 沼田 政嗣, 蓮池 悟, 山本 章二朗, 児玉 眞由美, 永田 賢治, 林 克裕, 下田 和哉
日本消化器病學會雜誌 = The Japanese journal of gastro-enterology 105 ( 9 ) 1362 - 1366 2008年9月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：一般財団法人 日本消化器病学会
症例は66歳男性．潰瘍性大腸炎(ulcerative colitis; UC）を合併したC型慢性肝炎(chronic hepatitis(C）; CH(C））に対して，インターフェロン(interferon; IFN）βの投与を行った．投与前の内視鏡的重症度は中等度であったが，投与開始後8週間で内視鏡的重症度は軽度となった．しかしIFN投与終了後は再び内視鏡的重症度は中等度となり，増悪を認めたため，IFN投与にて潰瘍性大腸炎が改善したと考えられた．<br>
-
[A case study: interferon-beta-induced remission of ulcerative colitis in a patient with type C chronic hepatitis].
Miike T, Tahara Y, Yamaguchi Y, Harada T, Abe H, Kusumoto K, Numata M, Hasuike S, Yamamoto S, Kodama M, Nagata K, Hayashi K, Shimoda K
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 105 ( 9 ) 1362 - 6 2008年9月
記述言語：日本語 掲載種別：研究論文（学術雑誌）
-
Development of ET, primary myelofibrosis, and PV in mice expressing JAK2 V617F. 査読あり
Shide Kotaro,Shimoda K Haruko,Kumano Takashi , Karube Kennosuke, Kameda Takurou, Takenaka Katsuto, Abe H, Oku Seido, Katayose K Keiko, Kusumoto Kazunori, Hasuike Satoru, Tahara Yoshihiro, Nagata Kenji, Matsuda Tadashi, Ohshima Koichi, Hrada Mine,Shimoda Kazuya
Leukemia 22 ( 1 ) 87 - 95 2008年1月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F
Shide K., Shimoda H., Kumano T., Karube K., Kameda T., Takenaka K., Oku S., Abe H., Katayose K., Kubuki Y., Kusumoto K., Hasuike S., Tahara Y., Nagata K., Matsuda T., Ohshima K., Harada M., Shimoda K.
Leukemia 22 ( 1 ) 87 - 95 2008年1月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Leukemia
An acquired JAK2 V617F mutation is found in most patients with polycythemia vera (PV), and about half of patients with essential thrombocythemia (ET) or primary myelofibrosis (PMF). Mice transplanted with bone marrow cells in which JAK2 V617F was retrovirally expressed developed PV-like features, but not ET or PMF. To address the contribution of this mutation to the pathogenesis of these three MPDs, we generated two lines of JAK2 V617F transgenic mice. One line showed granulocytosis after 4 months of age. Among 43 mice, 8 (19%) showed polycythemia and 15 (35%) showed thrombocythemia. The second line showed extreme leukocytosis and thromobocytosis. They showed anemia that means Hb value from 9 to 10g per 100ml when 1 month old. Myeloid cells and megakaryocytes were predominant in the bone marrow of these animals, and splenomegaly was observed. The expression of JAK2 V617F mRNA in bone marrow cells was 0.45 and 1.35 that of endogenous wild-type JAK2 in the two lines, respectively. In vitro analysis of bone marrow cells from both lines showed constitutive activation of ERK1/2, STAT5 and AKT, and augmentation of their phosphorylations by cytokine stimulation. We conclude that in vivo expression of JAK2 V617F results in ET-, PMF- and PV-like disease.
-
Transgenic expression of osteoactivin in the liver attenuates hepatic fibrosis in rats.
Abe H, Uto H, Takami Y, Takahama Y, Hasuike S, Kodama M, Nagata K, Moriuchi A, Numata M, Ido A, Tsubouchi H
Biochemical and biophysical research communications 356 ( 3 ) 610 - 5 2007年5月
-
Early diagnostic potential for hepatocellular carcinoma using the SELDI proteinChip system. 査読あり
Kanmura Shuji,Uto Hirofumi, Kusumoto Kazunori, Ishida Yoichi, Hasuike Satoru, Nagata Kennji, Hayashi Katsuhiro, Ido Akio, Sherri Oliver Stuver, Tsubouchi Hirohito:
Hepatology 45 ( 4 ) 948 - 956 2007年4月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
Early diagnostic potential for hepatocellular carcinoma using the SELDI ProteinChip system
Kanmura S., Uto H., Kusumoto K., Ishida Y., Hasuike S., Nagata K., Hayashi K., Ido A., Stuver S., Tsubouchi H.
Hepatology 45 ( 4 ) 948 - 956 2007年4月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Hepatology
Early detection of HCC increases the potential for curative treatment and improves survival. To facilitate early detection of HCC, this study sought to identify novel diagnostic markers of HCC using surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF/MS) ProteinChip technology. Serum samples were obtained from 153 patients with or without HCC, all of whom had been diagnosed with HCV-associated chronic liver disease. To identify proteins associated with HCC, serum samples were analyzed using SELDI-TOF/MS. We constructed an initial decision tree for the correct diagnosis of HCC using serum samples from patients with (n = 35) and without (n = 44) HCC. Six protein peaks were selected to construct a decision tree using this first group. The efficacy of the decision tree was then assessed using a second group of patients with (n = 29) and without (n = 33) HCC. The sensitivity and specificity of this decision tree for the diagnosis of HCC were 83% and 76%, respectively. For a third group, we analyzed sera from seven patients with HCC obtained before the diagnosis of HCC by ultrasonography (US) and from five patients free of HCC for the past 3 years. Use of these diagnostic markers predicted the diagnosis of HCC in six of these seven patients before HCC was clinically apparent without any false positives. Conclusion: Serum profiling using the SELDI ProteinChip system is useful for the early detection and prediction of HCC in patients with chronic HCV infection. Copyright © 2007 by the American Association for the Study of Liver Diseases.
DOI： 10.1002/hep.21598
-
Shirado A., Uto H., Kusumoto K., Kurogi J., Sakamoto H., Hasuike S., Nagata K., Hayashi K., Iwamitsu A., Hori T., Ibusuki K., Ido A., Tsubouchi H.
Japanese Journal of Gastroenterology 103 ( 7 ) 827 - 832 2006年7月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Japanese Journal of Gastroenterology
A 28-year-old woman was given a diagnosis of gastric endocrine cell carcinoma with multiple liver metastases in 1997. Chemotherapy was administered for treatment after a distal gastrectomy and hepatic tumor resection, and she had shown no sign of relapse after 2002. In February 2004, she was in the third month of pregnancy, and experienced recurrent liver metastasis. Although the tumor grew rapidly from 3cm to 10cm during her pregnancy, its size was significantly reduced with systemic chemotherapy after delivery. This is a rare case in which a liver metastasis of a gastric endocrine cell carcinoma grew during the course of pregnancy.